Kura Oncology, Inc.

KURASEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1422143

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	$53.9M	—	—	—
Research and Development Expense	$115.2M	$92.8M	$84.7M	$60.4M	$47.8M
Selling, General and Administrative Expense	$50.6M	—	—	—	—
Operating Expenses	$165.8M	$139.9M	$131.3M	$91.9M	$67.5M
Operating Income (Loss)	-$165.8M	-$139.9M	—	—	—
Interest Expense	—	—	$414.0K	$578.0K	$580.0K
Nonoperating Income (Expense)	$13.2M	$4.0M	$792.0K	$2.3M	$4.3M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$760.2M	$448.9M	$456.3M	$534.1M	$647.2M
Assets, Current	$744.8M	$432.5M	$446.4M	$522.3M	$637.3M
Cash and Cash Equivalents, at Carrying Value	$224.5M	$37.3M	$51.8M	$325.5M	$26.1M
Accounts Receivable, after Allowance for Credit Loss, Current	$2.1M	—	—	—	—
Inventory, Net	$0.00	—	—	—	—
Liabilities	$346.5M	$51.7M	$36.0M	$27.4M	$36.3M
Liabilities, Current	$78.7M	$35.3M	$24.1M	$22.5M	$26.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$124.8M	-$110.1M	-$104.6M	-$69.8M	-$54.8M
Net Cash Provided by (Used in) Investing Activities	$15.6M	$32.6M	-$126.8M	-$99.9M	-$46.3M
Net Cash Provided by (Used in) Financing Activities	$94.8M	$38.6M	-$3.4M	$469.3M	$111.1M
Payments to Acquire Property, Plant, and Equipment	$168.0K	$626.0K	$1.1M	$2.2M	$2.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)